Ultragenyx Pharmaceutical RARE
NASDAQ RARE
$15.28 +0.43 (+2.93%)
As of: Sep 4, 2026 · 3:59 PM EDT

Ultragenyx Pharmaceutical (RARE) Capital Leases (2019)

Ultragenyx Pharmaceutical (RARE) posted quarterly Capital Leases of $31.2 million for Q3 2019, down 5.34% quarter-over-quarter from $33.0 million in Q2 2019.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Ultragenyx Pharmaceutical (RARE) Capital Leases (2019) Analysis & Trends

Ultragenyx Pharmaceutical (RARE) has reported Capital Leases for 1 consecutive years, with $31.2 million the latest figure, recorded in Q3 2019.

Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Ultragenyx Pharmaceutical 1.56 Bn 1.27 Bn 180.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 31.21 Mn
Jun 30, 2019 32.97 Mn
Mar 31, 2019 22.98 Mn